How to Choose Between Imported and Domestic IVF Medications: Clinical Efficacy and Cost Difference Analysis

Direct answer to the beginning

Direct Clinical Answer: Domestic and imported IVF ovulation induction medications each have clear indications in clinical application, with no absolute superiority of one over the other. The choice of medication depends on a comprehensive assessment of the patient's age, ovarian reserve (AMH, AFC), previous ovarian response history, body mass index, and financial capacity. Imported recombinant FSH (e.g., Gonal-f, Puregon) offers high purity and batch-to-batch consistency, making it suitable for individuals with low ovarian reserve requiring precise control of ovarian response. Domestic medications (e.g., Lishenbao, Jin Sai Heng) cost approximately 50%–70% of imported ones, and for younger populations with normal ovarian reserve and good response, there is no significant difference in clinical outcomes.

1. Core Differences Between Domestic and Imported IVF Medications

Currently, the ovulation induction medications commonly used in clinical assisted reproduction in China are divided into two main categories based on source: recombinant FSH (primarily imported) and urinary-derived FSH (primarily domestic). There are clear differences in molecular structure, purity, batch consistency, and price. However, whether these differences translate into differences in clinical outcomes depends on the patient's specific biological characteristics.

2. Why There is a Difference

The essence of this issue is the balance between pharmacoeconomics and personalized medicine. The high purity and batch consistency of imported medications stem from recombinant DNA technology and strict manufacturing processes, giving them an advantage in the predictability of clinical response. Domestic medications, on the other hand, lower the treatment threshold through cost control, making ovulation induction cycles more affordable for a larger number of patients.

From a pharmacological perspective, the core active ingredient in ovulation induction medications is FSH. Regardless of the source, the ultimate target is the same—stimulating the growth and development of ovarian antral follicles. However, urinary-derived FSH contains trace LH activity (approximately 1–2 IU per 75IU), while recombinant FSH does not contain LH activity. This difference can influence clinical decisions in specific patient populations.

3. The Reproductive Specialist's Perspective: The Basis for Choice is Not "Imported or Domestic," but "Who It Suits"

In clinical decision-making, doctors do not simply recommend "imported is better" or "domestic is better." Instead, they make a comprehensive judgment based on the following indicators:

• Age & Ovarian Reserve: For age ≤35 years, AMH ≥2.0 ng/mL, AFC ≥12, domestic medications are sufficient to achieve an ideal number of follicles; for age ≥38 years, AMH <1.0 ng/mL, imported recombinant FSH is preferred to improve oocyte retrieval efficiency.
• Previous Ovarian Response History: If a previous cycle with domestic medications yielded satisfactory oocyte numbers and embryo quality, there is no reason to switch; if the response was poor (fewer oocytes than expected, uneven follicular development), a switch to imported medications may be considered.
• Body Mass Index (BMI): For individuals with BMI ≥28 kg/m², the total medication dose is usually higher, and domestic medications can significantly reduce cycle costs.
• Financial Factors: The cost of ovulation induction medications for a standard cycle is approximately 8,000–15,000 RMB (imported) vs. 4,000–8,000 RMB (domestic), a difference of about 5,000–7,000 RMB.

4. The Most Easily Overlooked Detail: Individual Variation in Drug Response is Greater Than the Difference in Drug Source

A common clinical observation is that the same patient using different brands of FSH shows no significant difference in follicular development rate, oocyte yield, or embryo quality. The key factors that truly influence ovulation induction outcomes are the patient's own ovarian reserve function, FSH receptor gene polymorphisms, and the compatibility of the treatment protocol.

For example, some patients may be more sensitive to the trace LH activity in urinary-derived FSH, potentially leading to premature luteinization or elevated progesterone; conversely, others may experience delayed follicular development due to insufficient LH activity. These details are often overlooked in routine assessments but are precisely the important basis for doctors to adjust the medication plan.

5. Two Common Pitfalls

Pitfall 1: Blindly Believing Imported Medications are Superior

Some patients believe that "expensive means better" and actively request imported medications. However, for young women with good ovarian reserve and normal response, there is no statistically significant difference in clinical pregnancy rates between domestic and imported medications. Spending several thousand extra yuan does not lead to improved outcomes.

Pitfall 2: Choosing Domestic Medications Solely to Save Money

For patients of advanced age, with low ovarian reserve (AMH <0.5 ng/mL), or those who have previously responded poorly to domestic medications, insisting on domestic medications may lead to insufficient oocyte retrieval and an increased cycle cancellation rate, ultimately costing more time and money.

6. Factors Affecting Cost: More Than Just the Drug Price

The cost of ovulation induction medications accounts for 20%–35% of the total cost of an entire IVF cycle. Choosing domestic or imported medications directly affects the total cycle cost, but the following hidden costs should also be considered:

• Total Medication Dose: Patients with poor ovarian reserve require higher doses, and the total cost of imported medications can reach 15,000–20,000 RMB.
• Cycle Cancellation Risk: If a cycle is cancelled due to poor drug response, the costs of preliminary examinations and medications are non-refundable.
• Embryo Quality & Number of Transfers: Insufficient oocyte yield can affect the number of embryos, potentially increasing the cumulative number of transfer cycles.
• Regional & Hospital Procurement Differences: Different reproductive centers have different procurement channels, and the price of the same medication can vary by 10%–20% between hospitals.

7. Medication Selection in Special Situations

8. Frequently Asked Clinical Questions

9. Practitioner Observation: Real-World Selection Trends

In recent clinical practice, the following trends have been observed:

• Approximately 60%–70% of patients in their first IVF cycle choose domestic medications, especially those aged <35 years with normal AMH.
• Imported medications are used at a higher rate (approximately 55%–65%) in populations with low ovarian reserve, advanced age, or a history of previous failure.
• Some reproductive centers use domestic medications as a first-line choice and imported medications as a second-line or targeted option to control overall treatment costs.
• With the introduction of domestic recombinant FSH (e.g., Jin Sai Heng), the purity gap between domestic and imported medications is narrowing, while the price advantage remains significant.